Zynex Shares Surge 48% Amid CEO Change and SEC Filing Delay
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Zynex, Inc. (NASDAQ: ZYXI) is a Colorado-based medical device company specializing in non-invasive electrotherapy and patient monitoring solutions. Founded in 1996 by Thomas Sandgaard, the company develops and markets devices for pain management, physical rehabilitation, neurological diagnosis, and cardiac monitoring. As of November 26, 2025, ZYXI shares closed at $1.09, reflecting a 47.82% increase on trading volume of 5,303,180 shares.
Corporate Structure and Leadership
Headquartered in Englewood, Colorado, Zynex operates through three subsidiaries:
- Zynex Medical, which produces home-use electrotherapy products (TENS, IFC, NMES) for pain management and stroke rehabilitation.
- Zynex Monitoring Solutions, which develops non-invasive cardiac monitoring systems for hospital settings.
- Zynex NeuroDiagnostics, which focuses on surface electromyography (EMG) and autonomic nervous system diagnostics.
According to LinkedIn, the company employs between 501 and 1,000 staff. On August 18, 2025, Steven Dyson assumed the role of Chief Executive Officer. Founder Thomas Sandgaard transitioned to Chairman of the Board.
Electrotherapy by Sarah Dao
Developments in 2025
- August 18, 2025: Steven Dyson began duties as CEO, with a mandate to optimize the company’s payer mix and refocus growth strategies.
- November 12, 2025: Zynex filed a Form NT 10-Q notifying the SEC of its inability to timely submit the quarterly report for the period ended September 30, 2025.
- November 17, 2025: The company filed its Form 10-Q for Q3 2025 and submitted a corresponding Form 8-K detailing current report items related to financial results and corporate governance.
Financial and Strategic Aspects
Zynex reported $144.81 million in trailing twelve-month revenue through September 30, 2025, with a net loss of $28.66 million and a profit margin of –19.79%. As of the most recent trading day, the market capitalization stood at $17.21 million. One equity research firm assigns a “Hold” rating with a $6.00 target price, citing medium industry and growth subratings alongside low management, safety, and financial strength subratings.
| Metric | Value |
|---|---|
| Share Price (11/26/2025) | $1.09 |
| 52-Week Range | $0.51 – $8.72 |
| Trailing Twelve-Month Revenue | $144.81 million |
| Net Income (TTM) | –$28.66 million |
| Profit Margin | –19.79% |
| Market Capitalization | $17.21 million |
| Analyst Rating | Hold (Target: $6.00) |
Zynex aims to leverage its FDA-cleared electrotherapy and monitoring devices to address trends in non-opioid pain management and expand hospital-based cardiac diagnostics.
Market Position and Industry Context
Zynex operates in the medical equipment manufacturing sector, competing with providers of electrotherapy and patient-monitoring solutions. The company’s TENS/IFC/NMES NexWave device and its CM-1500 Cardiac Monitor (FDA-cleared in February 2020) are part of its product portfolio. Industry trends toward outpatient care and remote monitoring may influence demand for home-use and hospital-based devices.
TL;DR
- ZYXI shares rose 47.82% to $1.09 on November 26, 2025, with volume exceeding 5.3 million.
- On August 18, 2025, Steven Dyson succeeded Thomas Sandgaard as CEO; Sandgaard remains Chairman.
- The company notified the SEC of a delayed Q3 2025 10-Q filing on November 12 and completed submissions on November 17, 2025.
- Trailing twelve-month revenue reached $144.81 million with a net loss of $28.66 million; market cap is $17.21 million.
- An independent analyst maintains a Hold rating and $6.00 target, noting mixed subratings across management, safety, financial strength, growth, and value.
- Zynex’s product portfolio aligns with industry trends toward non-opioid pain therapies and remote patient monitoring.